Everolimus and Zoledronic Acid in Patients With Renal Cell Carcinoma With Bone Metastases: A Randomized First-Line Phase II Trial

Micro-Abstract This study prospectively evaluated the benefits of the addition of bone-specific therapy to targeted therapy in patients with renal cell carcinoma metastatic to bone. Thirty patients were randomized to either everolimus alone or everolimus in combination with zoledronic acid. The stud...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical genitourinary cancer 2015-02, Vol.13 (1), p.50-58
Hauptverfasser:	Broom, Reuben J, Hinder, Victoria, Sharples, Katrina, Proctor, Janie, Duffey, Steven, Pollard, Stephanie, Fong, Peter C.C, Forgeson, Garry, Harris, Dean L, Jameson, Michael B, O'Donnell, Anne, North, Richard T, Deva, Sanjeev, Hanning, Fritha J, Grey, Andrew, Findlay, Michael P.N
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic Agents - administration & dosage Bisphosphonates Bone Density Conservation Agents - administration & dosage Bone Neoplasms - drug therapy Bone Neoplasms - secondary Carcinoma, Renal Cell - blood Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - urine Collagen Type I - blood Collagen Type I - urine Diphosphonates - administration & dosage Everolimus Female Hematology, Oncology and Palliative Medicine Humans Imidazoles - administration & dosage Kidney Neoplasms - blood Kidney Neoplasms - drug therapy Kidney Neoplasms - urine Male Middle Aged Neoplasm metastasis Peptides - blood Peptides - urine Prospective Studies Randomized controlled trial Sirolimus - administration & dosage Sirolimus - analogs & derivatives Skeletal-related events Targeted therapy Treatment Outcome Urology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Micro-Abstract This study prospectively evaluated the benefits of the addition of bone-specific therapy to targeted therapy in patients with renal cell carcinoma metastatic to bone. Thirty patients were randomized to either everolimus alone or everolimus in combination with zoledronic acid. The study found that this combination approach suppressed bone turnover and suggested prolonged tumor control.
ISSN:	1558-7673 1938-0682
DOI:	10.1016/j.clgc.2014.07.002